Recruiting

Klotho Plasmid Gene Therapy for Prevention in Humans

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This clinical trial aims to evaluate the safety and impact of Klotho plasmid gene therapy in humans for prevention purposes. We will measure changes in various biomarkers such as serum alpha-Klotho, FGF23, parathyroid hormone, vitamin D, phosphorus, and cystatin C levels, as well as monitor any adverse events.

What is being tested

Injectable Plasmid Klotho Gene Therapy

Genetic
Who is being recruted

From 23 to 90 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Phase 1
Interventional
Study Start: October 2025
See protocol details

Summary

Principal SponsorMinicircle
Study ContactMac Davis
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 6, 2025

Actual date on which the first participant was enrolled.

This study aims to explore the safety and effects of a new gene therapy involving the Klotho gene. The Klotho gene is thought to be beneficial for improving memory, kidney function, and overall health and longevity. This investigation is especially relevant for healthy individuals, as the therapy's potential to enhance general health and cognitive abilities could lead to better quality of life and longer lifespan. Understanding these effects may also help in developing treatments for age-related health issues. Participants in this study will undergo various health and cognitive assessments both before and after receiving the gene therapy. The therapy is administered through a small injection into the fat of the abdomen. To measure the results, researchers will conduct blood tests, health screenings, and cognitive evaluations at multiple points during the study. Although the study takes place outside of the U.S. for the treatment portion, the evaluations before and after the treatment will occur in the U.S. The assessments aim to determine any improvements in health and cognitive functions after receiving the therapy.

Official TitleEvaluating the Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans: An Interventional, Non-Placebo-Controlled Pilot Phase Study
NCT07216781
Principal SponsorMinicircle
Study ContactMac Davis
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

24 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 23 to 90 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

4 inclusion criteria required to participate
Participant is open to morphological change

If female, participant agrees to maintain contraception

If female, participant agrees to take a pregnancy test

If female, participant agrees to a pregnancy waiver

5 exclusion criteria prevent from participating
Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study

History of cancer diagnosis

Preexisting medical issues that may be exacerbated by the treatment

Has received any gene therapy within the past 12 months

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
This arm includes cognitive and health battery at multiple intervals pre- and post-administration of Klotho

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Recruiting

Apeiron Center

Austin, United StatesOpen Apeiron Center in Google Maps
Recruiting soon

GARM Clinic

Roatán, Honduras
Recruiting
2 Study Centers